First published in the Government *Gazette*, Electronic Edition, on 29 November 2019 at 5 pm.

No. S 791

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS
(AMENDMENT NO. 4)
REGULATIONS 2019

In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

Citation and commencement

1. These Regulations are the Misuse of Drugs (Amendment No. 4) Regulations 2019 and come into operation on 1 December 2019.

Amendment of Fourth Schedule

2. The Fourth Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

(*a*) by inserting, immediately after item (10) of paragraph 1, the following item:

"(11) N,N-Diethyl-3-hydroxy-7-methyl-2-oxo-4,6,6a,7,8,9-hexahydroindolo-[4,3-*fg*]quinoline-9-carboxamide (also known as 2-Oxo-3-hydroxy-LSD) and its acyclic secondary and tertiary amide structural isomers";

(*b*) by deleting items (13), (14) and (15) of paragraph 1 and substituting the following items:

"(13) 2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine or DMA) and its dimethoxy positional isomers in the phenyl ring

(14) N,α-Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxymethamphetamine or MDMA)

(15) 3-(1,2-Dimethylhepty1)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (also known as DMHP)";

(*c*) by deleting item (17) of paragraph 1 and substituting the following item:

"(17) 4-Ethyl-2,5-dimethoxy-α-methylphenethylamine (also known as DOET)";

(*d*) by deleting item (25) of paragraph 1 and substituting the following item:

"(25) 3-Methoxy-α-methyl-4,5-(methylenedioxy) phenethylamine (also known as 5-methoxy-MDA or MMDA)";

(*e*) by deleting item (28) of paragraph 1 and substituting the following item:

"(28) N-[α-Methyl-3,4-(methylenedioxy)phenethyl] hydroxylamine (also known as N-Hydroxy MDA)";

(*f*) by deleting item (36) of paragraph 1 and substituting the following item:

"(36) 3,4,5-Trimethoxy-α-methylphenethylamine (also known as TMA)";

(*g*) by inserting, immediately after item (8AA) of paragraph 15, the following item:

"(8AAB) 1-(4-Chlorophenyl)-2-(dimethylamino)propan-1-one (also known as 4-Chloro-N,N-dimethylcathinone)";

(*h*) by deleting item (13) of paragraph 15 and substituting the following item:

"(13) 2-(Ethylamino)-1-phenylpentan-1-one (also known as α-Ethylaminopentiophenone or N-Ethylpentedrone)";

(*i*) by deleting items (1), (1AAA), (1AA) and (1A) of paragraph 17 and substituting the following items:

"(1) 1-Acetyl-N,N-diethyllysergamide (also known as N-Acetyl-LSD or ALD-52) and its acyclic secondary and tertiary amide structural isomers

(1A) N-(1-Adamantyl)-5-bromopentyl-1H-indazole-3-carboxamide (also known as 5-Bromo-APINACA or 5-Bromo-AKB48) and its bromo positional isomers in the pentyl group

(1AA) 5-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl} pentanoic acid

(1AB) N-(1-Adamantyl)-5-chloropentyl-1H-indazole-3-carboxamide (also known as 5-Chloro-APINACA or 5-Chloro-AKB48) and its chloro positional isomers in the pentyl group

(1AC) N-(Adamant-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)

(1AD) N-(1-Adamantyl)-5-hydroxypentyl-1H-indazole-3-carboxamide and its hydroxy positional isomers in the pentyl group

(1AE) N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48) and its fluoro positional isomers in the phenyl ring

(1AF) N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group

(1AG) N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135) and its fluoro positional isomers in the pentyl group";

(*j*) by inserting, immediately after item (2A) of paragraph 17, the following items:

"(2AA) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) carbamoyl]-1H-indazole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers

(2AB) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) carbamoyl]-1H-indole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers";

(*k*) by inserting, immediately after item (2C) of paragraph 17, the following item:

"(2CA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-ADBICA) and its N-(1-amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the pentyl group";

(*l*) by inserting, immediately after item (2DA) of paragraph 17, the following item:

"(2DB) 5-{3-[(1-Amino-3-methyl-1-oxobutan-2-yl) carbamoyl]-1H-indazole-1-yl}pentanoic acid and its N-(1-amino-1-oxopentan-2-yl) isomers";

(*m*) by inserting, immediately after item (2G) of paragraph 17, the following item:

"(2GA) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide (also known as AB-FUBICA) and its N-(1-amino-1-oxopentan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring";

(*n*) by inserting, immediately after item (6F) of paragraph 17, the following item:

"(6G) [1-(5-Bromopent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Bromo-UR-144) and its bromo positional isomers in the pentyl group";

(*o*) by inserting, immediately after item (8AC) of paragraph 17, the following item:

"(8AD) [1-(5-Chloropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Chloro-UR-144) and its chloro positional isomers in the pentyl group";

(*p*) by inserting, immediately after item (19AA) of paragraph 17, the following item:

"(19AAB) Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AEB or 5-Fluoro-EMB-PINACA) and its pentanoate isomers and their respective fluoro positional isomers in the pentyl group";

(*q*) by deleting items (19ABA) and (19ABB) of paragraph 17 and substituting the following items:

"(19ABA) 2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective fluoro positional isomers in the phenyl ring

(19ABB) 2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid and its 1-pentanoic acid and 2-methylbutanoic acid isomers and their respective fluoro positional isomers in the phenyl ring

(19ABC) 2-[1-(4-Fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoic acid and its 1-pentanoic acid and 2-methylbutanoic acid isomers and their respective fluoro positional isomers in the phenyl ring

(19ABD) [1-(4-Fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as FUB-144 or FUB-UR-144) and its fluoro positional isomers in the phenyl ring

(19ABE) 2-[1-(4-Fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective fluoro positional isomers in the butyl group";

(*r*) by inserting, immediately after item (20C) of paragraph 17, the following item:

"(20D) 2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid and its 1-pentanoic acid and 2-methylbutanoic acid isomers and their respective fluoro positional isomers in the pentyl group";

(*s*) by inserting, immediately after item (27AA) of paragraph 17, the following item:

"(27AB) [1-(5-Hydroxypent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone and its hydroxy positional isomers in the pentyl group";

(*t*) by inserting, immediately after item (27E) of paragraph 17, the following item:

"(27F) N-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine (also known as 3-Methoxyphencyclidine or 3-Methoxy-PCP or 3-MeO-PCP) and its methoxy positional isomers in the phenyl ring";

(*u*) by inserting, immediately after item (28C) of paragraph 17, the following item:

"(28CA) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (also known as MDMB-4en-PINACA or MDMB-PINACA N1-pentyl-4-en isomer or MDMB(N)-022) and its hexanoate isomers and their respective pentenyl positional isomers in the pentyl group";

(*v*) by deleting item (28H) of paragraph 17 and substituting the following item:

"(28H) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AMB or 5-Fluoro-MMB-PINACA) and its pentanoate isomers and their respective fluoro positional isomers in the pentyl group";

(*w*) by inserting, immediately after item (28I) of paragraph 17, the following item:

"(28J) Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (also known as 5-Fluoro-MPP-PICA or 5-Fluoro-MPhP-PICA or MPHP-2201) and its fluoro positional isomers in the pentyl group";

(*x*) by inserting, immediately after item (38) of paragraph 17, the following item:

"(38AA) 4-{3-[(2-Phenylprop-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid and its phenylpropyl isomers"; and

(*y*) by inserting, immediately after item (39) of paragraph 17, the following item:

"(40) 5-[3-(2,2,3,3-Tetramethylcyclopropanecarbonyl)-1H-indol-1-yl]pentanoic acid".

[G.N. Nos. S 390/99; S 231/2000; S 436/2000; S 140/2001; S 492/2001; S 506/2005; S 490/2006; S 108/2007; S 525/2010; S 684/2010; S 270/2013; S 322/2014; S 571/2014; S 253/2015; S 199/2016; S 193/2017; S 234/2018; S 588/2018; S 88/2019; S 151/2019; S 353/2019]

Made on 29 November 2019.

PANG KIN KEONG
Permanent Secretary,
Ministry of Home Affairs,
Singapore.

[MHA 112/2/0049; AG/LEGIS/SL/185/2015/2 Vol. 2]